Opexa Therapeutics (OPXA) Announces 40% Workforce Reduction
- Wall Street falls as post-election winners lag
- The FTC Confirms Antitrust Charges Against Qualcomm (QCOM) for Monopolizing Semiconductor Device Used in Cell Phones
- United Airlines (UAL) Tops Q4 EPS by 5c
- BAT Reaches Deal to Acquire Reynolds American (RAI) for $49 Billion
- Deutsche Bank (DB) Agrees to Pay $7.2B for Misleading Investors in Sale of RMBS
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Opexa Therapeutics (Nasdaq: OPXA) nnounced that it was implementing an approximately 40% reduction to the Company’s current workforce in order to reduce operating expenses and conserve cash resources. The move comes as the Company recently announced that the Phase 2b Abili-T clinical trial designed to evaluate the efficacy and safety of Tcelna® (imilecleucel-T) in patients with secondary progressive multiple sclerosis (SPMS) did not meet its primary endpoint of reduction in brain volume change (atrophy), nor did it meet the secondary endpoint of reduction of the rate of sustained disease progression.
The Company estimates that it will incur incremental aggregate cash charges of approximately $95,000 associated with this current workforce reduction. Moreover, the Company expects that additional restructuring will occur by year-end.
Additionally, the Company has accepted the resignations of Ms. Donna Rill, Opexa’s Chief Development Officer, and Mr. Scott Seaman, a member of the Company’s Board of Directors. Ms. Rill, who is leaving to pursue other career opportunities, will depart as of November 4, 2016.
“This reduction in force is a difficult but necessary step as a result of the disappointing results of our lead product candidate, Tcelna, announced last week,” said Neil K. Warma, President and Chief Executive Officer of Opexa. “I would like to personally express my appreciation to each of the employees impacted by this decision for their commitment to Tcelna and Opexa. The Opexa team has endeavored to increase the understanding of secondary progressive multiple sclerosis, and we hope our work will contribute to the development of a safe and effective therapy for this devastating disease. I would also like to thank Scott Seaman for his long-time service as a Director of Opexa and note our special heartfelt appreciation of Donna Rill who has dedicated over 15 years to Opexa.”
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Christopher & Banks (CBK) Announces Departure of CEO, Trims Q4 Guidance
- Banks Rejected by Supreme Court, Lose Bid to Derail Libor Suits - Bloomberg
- Caesars Entertainment (CZR) Announces Confirmation of CEOC's Plan of Reorganization
Create E-mail Alert Related CategoriesCorporate News, Guidance, Hot Corp. News, Management Changes, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!